Spectroscopic analysis of tongue cancer tissue during surgery
Official title: Prospective Analysis of Tumor Tissues From the Oral Cavity by SpiderMassTM Spectroscopy
Run by Centre Hospitalier Universitaire, Amiens · NCT05104619 · Data updated 2026-11-12
Researchers will use a real-time spectroscopic tool during tongue cancer surgery to see if tissue looks cancerous or not, helping guide removal in patients with squamous cell carcinoma of the tongue.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens, Picardie) |
| Status | Recruiting |
| Started | March 10, 2021 |
| Main results expected | October 2026 |
| Study ends | October 2026 |
| Registry record updated | June 15, 2026 |
| Trial ID | NCT05104619 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with squamous cell carcinoma of the tongue undergoing primary surgical resection (T1–T4).
✕Probably not a fit
Patients with metastatic disease or those receiving neoadjuvant therapies are less likely to benefit from intraoperative spectroscopic analysis for margin assessment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study examines whether real-time spectroscopic analysis of tongue tissue can differentiate cancerous from non-cancerous tissue during surgical resection. The study focuses on patients with squamous cell carcinoma of the tongue undergoing primary tongue surgery, aiming to correlate spectral patterns with margin status. SpiderMass technology is used to obtain molecular profiles in the operating room to support intraoperative decisions. No randomized treatment is involved; instead, the goal is to improve accuracy of surgical margins and potentially influence future management. The study collects tissue spectra and compares them to histopathological margin results.
Why it matters
Potential benefit: If successful, real-time tissue analysis could improve surgical margin assessment and inform immediate decisions in tongue cancer surgeries.
How similar studies have gone: Previous work with real-time tissue spectroscopy has shown promise in distinguishing cancerous tissue in head and neck cancers, but broader validation is needed for routine intraoperative use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age : 18 years and older * squamous cell carcinoma of the tongue * surgical resection as first-line treatment * tumor classification T1 to T4. Exclusion Criteria: * metastatic disease * neoadjuvant therapies
Where it's running
-
Centre Hospitalier Universitaire d'Amiens
Amiens, Picardie, France Recruiting
Study contacts
- Study coordinator: Christophe ATTENCOURT, MD
- Email: attencourt.christophe@chu-amiens.fr
- Phone: 03 22 66 87 66
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Two-photon microscopy on skin biopsies to help diagnose skin lesions
This study tests whether images from two-photon fluorescence microscopy of dermatology biopsies can match the diagnosis determined by standard histology.
-
Targeted dual-imaging helper for head and neck cancer surgery
This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)
A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.
-
Omitting postoperative radiation after HPV-related oropharyngeal cancer guided by ctHPVDNA monitoring
This study tests whether some patients with HPV-related OPSCC can skip postoperative radiation after surgery if their tumors are low risk and ctHPVDNA looks negative.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.